Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

Background Treatment options are sparse for patients with advanced cholangiocarcinoma
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …

Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR)
signaling has crucial roles in a multitude of processes during embryonic development and …

Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Background Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the
pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …

Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …